Myriad Genetics: Business Model, SWOT Analysis, and Competitors 2026

Myriad Genetics, Inc. stands as a leading company in Healthcare. Generating $824.50 million in annual revenue (growing -0.4% year-over-year) and carrying a market capitalization of $479.70 million, the company has cemented its position as a foundational player in the global Diagnostics & Research landscape. Under the leadership of its leadership team, Myriad Genetics, Inc. continues to execute on a multi-year strategic vision that balances growth investment with shareholder returns.

This in-depth analysis examines Myriad Genetics, Inc.'s business model, financial performance, competitive positioning, and SWOT analysis as of 2026. Whether you're evaluating Myriad Genetics, Inc. as an investment, benchmarking it against peers, or researching its strategy, this guide covers the key factors that define Myriad Genetics, Inc.'s position in the Diagnostics & Research market today.

What You Will Learn

1. How Myriad Genetics, Inc. generates revenue across its key business segments and the unit economics behind each
2. A data-backed SWOT analysis covering Myriad Genetics, Inc.'s competitive strengths, operational weaknesses, market opportunities, and external threats
3. Who Myriad Genetics, Inc.'s main competitors are and how the company compares on key financial metrics
4. Myriad Genetics, Inc.'s key financial metrics: revenue, profit margins, market cap, free cash flow, and valuation multiples
5. Myriad Genetics, Inc.'s strategic direction and what to watch in 2026-2027

Key Takeaways

• Revenue: $824.50 million annual revenue (TTM), +-0.4% YoY
• Market Cap: $479.70 million — one of the largest companies in the Healthcare sector
• Profitability: Gross margin 69.9%, operating margin -1.4%, net margin -44.4%
• Free Cash Flow: $762,500
• Return on Equity: -68.5% — reflects current investment phase
• Employees: 2,700 worldwide

Who Owns Myriad Genetics, Inc.?

Myriad Genetics, Inc. is publicly traded on the NMS under the ticker symbol MYGN. As a public company, it is owned by millions of shareholders ranging from retail investors to major institutional holders.

The largest shareholders of Myriad Genetics, Inc. are typically major institutional investors including The Vanguard Group, BlackRock, and State Street Corporation — which collectively often hold 15-25% of publicly traded US companies. Insider ownership and the concentration of voting rights vary; investors should review the latest proxy statement filed with the SEC for precise ownership data.

Myriad Genetics, Inc. has approximately 0.09 billion shares outstanding, with float shares of 0.00 billion — the freely tradeable portion. The stock trades at $5.13 per share as of early 2026.

Myriad Genetics, Inc.'s Mission Statement

Myriad Genetics, Inc.'s strategic mission is aligned with its core business activities in the Diagnostics & Research sector. The company's stated values and mission inform its capital allocation decisions, talent strategy, and long-term product roadmap. Mission statements for public companies are disclosed in annual reports and investor presentations — Myriad Genetics, Inc.'s most recent proxy statement and annual report are the authoritative sources for its current mission and values.

A company's mission statement matters because it signals strategic intent to employees, investors, and customers. For Myriad Genetics, Inc., the mission encompasses not just what the company does, but why it exists and how it creates value for stakeholders. Companies that maintain alignment between their stated mission and actual capital allocation decisions tend to build stronger brand trust and employee engagement over time.

In practice, Myriad Genetics, Inc.'s strategic priorities as communicated to investors in 2025-2026 center on revenue growth and market share expansion, profitability improvement, and sustainable returns of capital to shareholders. These operational priorities translate directly into the business model and investment thesis discussed in the following sections.

How Does Myriad Genetics, Inc. Make Money?

Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the ag

Myriad Genetics, Inc.'s business model is built around delivering value to its customers in the Diagnostics & Research segment of the Healthcare sector. The company generates revenue through its core product and service offerings, leveraging its market position, operational capabilities, and customer relationships to sustain competitive advantage. Like most companies in Diagnostics & Research, Myriad Genetics, Inc.'s financial performance is influenced by industry-wide pricing dynamics, input costs, and the balance between volume growth and margin management.

Management's strategic priorities — as disclosed in investor communications — focus on sustainable revenue growth, disciplined capital allocation, and building long-term shareholder value. Investors should review Myriad Genetics, Inc.'s latest annual report (10-K or equivalent) and quarterly earnings releases for the most current financial disclosures and strategic updates.

Myriad Genetics, Inc. Business Model Canvas

The Business Model Canvas framework provides a structured view of how Myriad Genetics, Inc. creates, delivers, and captures value.

Key Partners: Myriad Genetics, Inc.'s key partners include suppliers, distributors, technology providers, and strategic alliances that enable its core operations. In the Diagnostics & Research sector, these relationships provide supply chain resilience, expanded distribution, and access to complementary capabilities.

Key Activities: Myriad Genetics, Inc.'s most important activities center on product development and innovation, sales and marketing, supply chain management, customer service, and regulatory compliance. The company's ability to execute these activities at scale is a core competency.

Key Resources: Myriad Genetics, Inc.'s critical resources include its brand equity, intellectual property portfolio, customer relationships, human capital (2,700 employees), proprietary technology, and financial resources ($149.60M in cash).

Value Propositions: Myriad Genetics, Inc. delivers value to customers through product quality, brand trust, convenience, innovation, and price competitiveness. The specific value proposition varies by customer segment but consistently addresses core needs in the Diagnostics & Research market.

Customer Relationships: Myriad Genetics, Inc. maintains customer relationships through multiple channels including direct sales teams, digital platforms, customer service centers, and loyalty/membership programs. Customer retention is a key operational priority.

Channels: Myriad Genetics, Inc. reaches customers through its own direct channels (stores, website, apps), third-party retailers and distributors, and partner networks. The mix of direct vs. indirect channels affects margin structure and customer data ownership.

Customer Segments: Myriad Genetics, Inc. serves multiple distinct customer segments, which may include consumers, small and medium businesses, enterprise clients, and government entities — depending on its product portfolio and market positioning.

Cost Structure: Myriad Genetics, Inc.'s major costs include cost of goods sold (30.1% of revenue), research & development, sales & marketing, general & administrative expenses, and capital expenditures. Total operating costs represent 101.4% of revenue.

Revenue Streams: Myriad Genetics, Inc. generates revenue through its core product and service offerings.

Myriad Genetics, Inc. Competitors

Myriad Genetics, Inc.'s main competitors include Invitae Corporation, Genomic Health (a subsidiary of Exact Sciences), Natera, Inc, Ambry Genetics. The company operates in the Diagnostics & Research segment of the Healthcare sector where competitive positioning is shaped by product quality, distribution scale, and brand strength.

Competitive Analysis

Myriad Genetics, Inc.'s competitive position in Diagnostics & Research is defined by its $479.70M market capitalization and 69.9% gross margins. Key competitive advantages include brand recognition and operational scale in the Diagnostics & Research market.

Myriad Genetics, Inc. SWOT Analysis

A SWOT analysis examines Myriad Genetics, Inc.'s internal strengths and weaknesses alongside external opportunities and threats.

Strengths

• Strong Margins: Myriad Genetics, Inc.'s gross margin of 69.9% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of -1.4% demonstrates disciplined cost management even at scale.

Weaknesses

• Leverage Risk: Myriad Genetics, Inc.'s debt-to-equity ratio of 57.0 indicates meaningful financial leverage. Total debt stands at $209.80M against $149.60M in cash and equivalents.
• Revenue Decline: Year-over-year revenue declined 0.4%, raising questions about demand for Myriad Genetics, Inc.'s core offerings and requiring management to articulate a credible recovery path.

Opportunities

• Total Addressable Market: Myriad Genetics, Inc. operates in the Diagnostics & Research segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this environment translate to meaningful revenue upside, particularly as the company expands its product portfolio and geographic reach.
• International Expansion: Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Myriad Genetics, Inc.'s products and services.
• Strategic Acquisitions: With $149.60M in cash and strong free cash flow generation, Myriad Genetics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.

Threats

• Macroeconomic Sensitivity: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Myriad Genetics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scenario could meaningfully impact demand.
• Regulatory and Geopolitical Risk: Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Myriad Genetics, Inc.'s business model across key markets.
• Talent Competition: Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly critical in an era of AI-driven competition.

Conclusion

Myriad Genetics, Inc. enters 2026 as a leading company in Healthcare, backed by $824.50 million in annual revenue and a -44.4% net profit margin. The company's 69.9% gross margins and $762,500 in free cash flow provide the financial foundation to fund growth initiatives while returning capital to shareholders.

The primary opportunities ahead lie in expanding market share, operational efficiency improvements, and selective geographic expansion. The key risks to monitor include competitive pressure from established peers and new entrants, macroeconomic headwinds, and regulatory developments in Myriad Genetics, Inc.'s core markets.

For investors and analysts, Myriad Genetics, Inc. represents an important company to understand within the Healthcare sector. Key metrics to track include revenue growth, margin trends, and competitive positioning updates.

Data Sources

Financial data and business information for this analysis was sourced from: Yahoo Finance – Myriad Genetics, SEC EDGAR – Myriad Genetics Filings, and Myriad Genetics's investor relations materials.

All financial figures reflect the most recent publicly available disclosures. Investors should verify current data before making investment decisions.

Frequently Asked Questions

1. Q1: What types of tests does Myriad Genetics offer?

Myriad Genetics, Inc. generated $824.50 million in annual revenue with a -44.4% net profit margin as of the latest reporting period. The company operates in the Diagnostics & Research sector. For the most current information, consult Myriad Genetics, Inc.'s investor relations page.

2. Q2: How does Myriad Genetics ensure the accuracy of its tests?

Myriad Genetics, Inc. generates $824.50 million in annual revenue (TTM) with a 69.9% gross margin, growing -0.4% year-over-year. The company's revenue model is described in detail in the business model section above.

3. Q3: What is the significance of genetic testing in personalized medicine?

Myriad Genetics, Inc. generated $824.50 million in annual revenue with a -44.4% net profit margin as of the latest reporting period. The company operates in the Diagnostics & Research sector. For the most current information, consult Myriad Genetics, Inc.'s investor relations page.

4. Q4: How does Myriad Genetics respond to competitive pressures in the market?

Myriad Genetics, Inc. generates $824.50 million in annual revenue (TTM) with a 69.9% gross margin, growing -0.4% year-over-year. The company's revenue model is described in detail in the business model section above.

5. Q5: What are the challenges facing Myriad Genetics?

Myriad Genetics, Inc. faces the following external threats: Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Myriad Genetics, Inc.'s revenue is not fully insulated from macroeconomic cycles, and a rece Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Myriad Genetics, In Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri Monitoring these risks is essential for investors tracking the company's long-term trajectory.

6. Q6: How can individuals access Myriad Genetics' tests?

Myriad Genetics, Inc. generated $824.50 million in annual revenue with a -44.4% net profit margin as of the latest reporting period. The company operates in the Diagnostics & Research sector. For the most current information, consult Myriad Genetics, Inc.'s investor relations page.

7. Q7: What is the future outlook for genetic testing?

Myriad Genetics, Inc.'s key growth opportunities include: Myriad Genetics, Inc. operates in the Diagnostics & Research segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Myriad With $149.60M in cash and strong free cash flow generation, Myriad Genetics, Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.